Q-omics provides the consensus-scored LINC01613 profile across patient tissues and cancer cell-line models. LINC01613 expression is associated with patient survival in 11 of 34 cancer types, with the highest sampling consensus in ESCA. Among the 18 cancer types available for tumor–normal comparison, LINC01613 is differentially expressed in 5, with the highest sampling consensus in KIRC. Additionally, LINC01613 RNA expression shows 4,914 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight ESCA, KIRC, and STAD as cancer lineages where LINC01613 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC01613 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC01613 survival associations across molecular data types. LINC01613 RNA expression shows survival associations in the most cancer types (11). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC01613 RNA expression–survival associations across cancer types. High LINC01613 expression shows unfavorable associations in ESCA, LIHC and BRCA, but favorable associations in HNSC, LUSC and LUAD. The ESCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .008). Together, the overview and detailed table identify ESCA as the clearest survival context for LINC01613 RNA expression.
This table summarizes LINC01613 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for LINC01613. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC01613 shows lower tumor expression in KIRC, THCA, KIRP and LUSC and higher tumor expression in KICH. The KIRC box plot shows higher LINC01613 RNA expression in normal versus tumor tissue (log2 FC = −0.009, t-test p < 0.001).
This table shows molecular features associated with LINC01613 in patient tissues and cancer cell lines. In patient samples, LINC01613 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
